Compare · AIRS vs HIMS
AIRS vs HIMS
Side-by-side comparison of AirSculpt Technologies Inc. (AIRS) and Hims & Hers Health Inc. (HIMS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIRS and HIMS operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- HIMS is the larger of the two at $7.41B, about 38.5x AIRS ($192.5M).
- HIMS has been more active in the news (24 items in the past 4 weeks vs 5 for AIRS).
- HIMS has more recent analyst coverage (25 ratings vs 8 for AIRS).
- Company
- AirSculpt Technologies Inc.
- Hims & Hers Health Inc.
- Price
- -
- -
- Market cap
- $192.5M
- $7.41B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2019
- News (4w)
- 5
- 24
- Recent ratings
- 8
- 25
AirSculpt Technologies Inc.
AirSculpt Technologies, Inc. focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. It offers custom body contouring using its AirSculpt procedure that removes unwanted fat in a minimally invasive procedure. The company provides fat removal procedures across treatment areas; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. Its body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. As of October 5, 2021, it operated 16 centers across 13 states. The company was founded in 2012 and is headquartered in Miami Beach, Florida.
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
Latest AIRS
- Amendment: SEC Form SCHEDULE 13G/A filed by AirSculpt Technologies Inc.
- SEC Form 10-Q filed by AirSculpt Technologies Inc.
- AirSculpt Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results
- AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Second Quarter Fiscal 2026 Results
- AirSculpt Technologies Announces Participation in Upcoming Investor Conferences
- Director Feinstein Adam T disposed of 5,169,820 shares (SEC Form 4)
- Director Higgins Kenneth was granted 100,286 shares, increasing direct ownership by 58% to 274,066 units (SEC Form 4)
- Director Aaron Thomas J was granted 100,286 shares, increasing direct ownership by 57% to 276,866 units (SEC Form 4)
- Director Chu Caroline was granted 100,286 shares, increasing direct ownership by 57% to 277,066 units (SEC Form 4)
Latest HIMS
- Chief Policy Officer Autor Deborah M. sold $467,128 worth of shares (16,773 units at $27.85) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 48,961 units (SEC Form 4)
- Chief Financial Officer Okupe Oluyemi sold $148,111 worth of shares (4,938 units at $29.99) as part of a pre-agreed trading plan and exercised 4,938 shares at a strike of $5.01 (SEC Form 4)
- Chief Legal Officer Boughton Soleil sold $691,808 worth of shares (25,111 units at $27.55) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 313,964 units (SEC Form 4)
- Chief Legal Officer Boughton Soleil converted options into 42,261 shares and covered exercise/tax liability with 21,500 shares, increasing direct ownership by 7% to 339,075 units (SEC Form 4) to satisfy tax liability
- Chief Medical Officer Carroll Patrick Harrison converted options into 26,187 shares and covered exercise/tax liability with 10,201 shares, increasing direct ownership by 9% to 197,847 units (SEC Form 4) (for tax liability)
- Director Schultz Kare converted options into 6,623 shares, increasing direct ownership by 34% to 26,020 units (SEC Form 4)
- Chief Policy Officer Autor Deborah M. converted options into 32,920 shares and covered exercise/tax liability with 16,147 shares, increasing direct ownership by 34% to 65,734 units (SEC Form 4) to satisfy withholding tax
- CTO Elshenawy Mohamed converted options into 188,285 shares and covered exercise/tax liability with 95,798 shares, increasing direct ownership by 92% to 193,510 units (SEC Form 4) (tax withholding)
- Chief Operating Officer Chi Michael converted options into 86,265 shares and covered exercise/tax liability with 47,702 shares, increasing direct ownership by 9% to 470,687 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Dudum Andrew converted options into 154,993 shares and covered exercise/tax liability with 78,859 shares, increasing direct ownership by 8% to 1,033,177 units (SEC Form 4) to satisfy withholding obligation